arrow
G

Gianantonio Rosti

IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
H指数:62
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study

年龄和性别对慢性髓性白血病患者在一线治疗中分子反应的影响:一项意大利CML网络队列研究

2026-04-180
OAAI
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study

在Nilotinib减量后的慢性期慢性髓性白血病中的无治疗缓解:DANTE研究的96周更新

2025-08-080
OAAI
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

慢性期慢性髓性白血病患者2期Optic研究的5年随访:疗效、安全性及首次治疗结束突变结果

BLOOD
IF23.1
2024-11-050
PRE
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

更正: 来自PACE和OPTIC试验的慢性期慢性粒细胞白血病 (cp-cml) 患者的泊那替尼剂量修改动力学

LEUKEMIA
IF13.4
2024-09-020
OAAI
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

来自PACE和OPTIC试验的慢性期慢性粒细胞白血病 (cp-cml) 患者的ponatinib剂量修改动力学

LEUKEMIA
IF13.4
2024-01-2913
OAAI
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
CANCER
IF5.1
2023-10-063
OAAI
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials

尼洛替尼作为一线治疗老年 (> 65岁) 慢性粒细胞白血病患者的疗效和安全性

2023-04-206
OAAI
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
2022-08-3032
OAAI
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow- up of the GIMEMA CML 0307 study
2022-04-0714
OAAI
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study

低剂量TKIs治疗慢性粒细胞白血病患者的无治疗缓解: 在现实生活中也是可行的选择。校园CML研究

2022-03-036
OAAI
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
2021-10-188
OAAI
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
2021-08-2613
OAAI